Tailin biotech (300813.SZ) released its performance report for the first half of the year, with a net profit attributable to the parent company of 13.5429 million yuan, representing a growth of 105.76%.

Wisdom Finance and Economics APP News, Tailin Biology (300813.SZ) released its semi-annual report for 2025. The company's operating income was 146 million yuan, a decrease of 6.69% year-on-year. Net profit attributable to shareholders of the listed company was 13.5429 million yuan, an increase of 105.76% year-on-year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.2038 million yuan, an increase of 116.80% year-on-year. Basic earnings per share were 0.11 yuan. In addition, it is proposed to distribute a cash dividend of 1 yuan (tax included) per 10 shares to all shareholders.